Cellectis S.A. (CLLS) Key Metrics
CLLS valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $104.8M
- Enterprise value
- $78.3M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.6 10-yr median 14.9
- Price / book
- 3.9 10-yr median 2.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.91
CLLS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCLLS valuation Price multiples at each fiscal year-end price.
Price / sales+69.4%
6.7
2025 · hover or tap a bar for each year
20162025
Price / book+414.0%
6.4
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−20.7 pts
−8.8%
2025 · hover or tap a bar for each year
20162025
CLLS returns How much profit the business earns on the capital it uses.
Return on equity−31.2 pts
−65.3%
2025 · hover or tap a bar for each year
20162025
Return on assets−8.8 pts
−19.1%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin−105.3 pts
−58.3%
2025 · hover or tap a bar for each year
20162025
Asset turnover+78.1%
0.21
2025 · hover or tap a bar for each year
20162025
CLLS per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+58.7%
$0.73
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$0.67
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$0.42
2025 · hover or tap a bar for each year
20162025
Book value per share−47.7%
$0.76
2025 · hover or tap a bar for each year
20162025
Dividends per share
$0.00
2025 · hover or tap a bar for each year
20162025
Shares outstanding+10.7%
100.3M
2025 · hover or tap a bar for each year
20162025
CLLS financial health Debt, liquidity and how easily interest is covered.
Debt / equity+126.3%
1.58
2025 · hover or tap a bar for each year
20162025
Net debt+$80.1M
−$88.8M
2025 · hover or tap a bar for each year
20162025
Current ratio−6.1%
1.62
2025 · hover or tap a bar for each year
20162025
Interest coverage
-4.1
2025 · hover or tap a bar for each year
20162025
Debt / assets+54.8%
0.37
2025 · hover or tap a bar for each year
20162025
CLLS efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−82 days
121 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−80 days
670 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−2 days
-549 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue−3.0 pts
3.2%
2025 · hover or tap a bar for each year
20162025
CLLS valuation history
Fiscal year-endToday10-year median
CLLS returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CLLS debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CLLS cash returned to shareholders
DividendsBuybacksFree cash flow
CLLS price vs earnings per share
Share price at year-endEPS (right axis)
CLLS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $485.4M | $163.0M | $175.6M | $95.7M | $344.7M | $1.15B | $726.6M | $678.9M | $1.04B | $607.0M |
| Enterprise value | $396.6M | −$5.8M | $56.8M | $73.7M | $259.4M | $988.6M | $413.3M | $228.4M | $743.4M | $318.3M |
| Price / sales | 6.7 | 3.9 | 232.6 | 5.0 | 4.7 | 15.6 | 47.8 | 53.3 | 41.3 | 14.3 |
| Price / book | 6.4 | 1.2 | 2.1 | 0.8 | 1.6 | 4.1 | 2.3 | 1.7 | 3.9 | 2.2 |
| Price / free cash flow | — | 8.3 | — | — | — | — | — | — | — | — |
| Price / operating cash flow | — | 7.4 | — | — | — | — | — | — | — | — |
| EV / sales | 5.4 | -0.1 | 75.3 | 3.8 | 3.5 | 13.4 | 27.2 | 17.9 | 29.5 | 7.5 |
| Earnings yield | −13.9% | −22.6% | −57.6% | −103.2% | −25.0% | −6.3% | −12.5% | −11.6% | −9.6% | −10.5% |
| Free cash flow yield | −8.8% | 12.0% | −14.7% | −94.0% | −35.7% | −10.8% | −11.3% | −10.8% | −5.3% | −7.3% |
| Dividend yield | 0.0% | 0.0% | 0.0% | 0.6% | 0.0% | 0.0% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.3% | 1.2% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $4.84 | $1.80 | $3.08 | $2.10 | $8.12 | $27.06 | $17.12 | $16.65 | $29.15 | $16.95 |
| Per share | ||||||||||
| Revenue per share | $0.73 | $0.46 | $0.01 | $0.42 | $1.74 | $1.74 | $0.36 | $0.31 | $0.71 | $1.19 |
| Earnings per share | −$0.67 | −$0.41 | −$1.77 | −$2.17 | −$2.03 | −$1.71 | −$2.14 | −$1.93 | −$2.78 | −$1.78 |
| Operating cash flow per share | −$0.40 | $0.24 | −$0.43 | −$1.92 | −$2.46 | −$1.89 | −$1.63 | −$1.67 | −$1.47 | −$0.87 |
| Free cash flow per share | −$0.42 | $0.22 | −$0.45 | −$1.97 | −$2.90 | −$2.93 | −$1.93 | −$1.79 | −$1.54 | −$1.24 |
| Cash per share | $2.08 | $2.87 | $3.57 | $2.14 | $4.39 | $6.31 | $8.50 | $11.08 | $8.32 | $8.11 |
| Book value per share | $0.76 | $1.45 | $1.49 | $2.59 | $5.21 | $6.68 | $7.42 | $10.04 | $7.48 | $7.65 |
| Tangible book value per share | $0.75 | $1.43 | $1.47 | $2.57 | $5.17 | $6.64 | $7.40 | $10.01 | $7.44 | $7.61 |
| Dividends per share | $0.00 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | — | — | — | — |
| Capex per share | $0.02 | $0.03 | $0.02 | $0.05 | $0.44 | $1.05 | $0.31 | $0.12 | $0.07 | $0.37 |
| Debt per share | $1.20 | $1.01 | $1.49 | $1.66 | $2.38 | $2.51 | $1.12 | $0.03 | $0.00 | $0.05 |
| Shares outstanding | 100.3M | 90.6M | 57.0M | 45.6M | 42.4M | 42.5M | 42.4M | 40.8M | 35.7M | 35.8M |
| Change in shares outstanding | +10.7% | +58.9% | +25.2% | +7.3% | −0.1% | +0.1% | +4.1% | +14.2% | −0.3% | +3.7% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −65.3% | −34.1% | −99.7% | −58.2% | −34.2% | −24.2% | −25.0% | −23.3% | −36.7% | −22.7% |
| Return on invested capital (ROIC) | — | — | — | −61.0% | −52.3% | −108.8% | — | — | — | — |
| Return on assets (ROA) | −19.1% | −10.2% | −33.9% | −30.7% | −20.3% | −15.5% | −18.7% | −18.9% | −29.9% | −18.2% |
| Return on tangible assets | −20.9% | −9.6% | −30.3% | −37.9% | −22.7% | −15.5% | −19.4% | −15.8% | −30.0% | −19.4% |
| Free cash flow margin | −58.3% | 47.0% | — | −468.9% | −166.5% | −168.6% | −540.5% | −573.6% | −218.3% | −104.3% |
| Financial health | ||||||||||
| Total debt | $119.9M | $91.5M | $85.1M | $75.8M | $100.9M | $106.7M | $47.6M | $1.4M | $34,000 | $1.8M |
| Cash & short-term investments | $208.7M | $260.3M | $203.8M | $97.7M | $186.1M | $268.2M | $360.9M | $451.9M | $297.0M | $290.5M |
| Net debt | −$88.8M | −$168.8M | −$118.8M | −$21.9M | −$85.3M | −$161.6M | −$313.3M | −$450.5M | −$296.9M | −$288.7M |
| Debt / equity | 1.58 | 0.70 | 1.00 | 0.64 | 0.46 | 0.38 | 0.15 | 0.00 | 0.00 | 0.01 |
| Debt / assets | 0.37 | 0.24 | 0.25 | 0.29 | 0.26 | 0.23 | 0.10 | 0.00 | 0.00 | 0.01 |
| Current ratio | 1.62 | 1.73 | 1.50 | 2.28 | 4.57 | 6.06 | 6.25 | 10.40 | 7.42 | 5.56 |
| Quick ratio | 1.62 | 1.73 | 1.50 | 1.94 | 4.57 | 6.03 | 6.21 | 10.40 | 7.42 | 5.56 |
| Interest coverage | -4.1 | -8.0 | -18.3 | -23.7 | -16.0 | -7.1 | -47.4 | — | -165.4 | — |
| Working capital | $90.5M | $120.8M | $77.9M | $80.8M | $176.1M | $263.3M | $328.9M | $440.8M | $279.7M | $255.7M |
| Invested capital | −$12.9M | −$37.8M | −$34.1M | $96.0M | $136.0M | $122.2M | $1.8M | −$41.2M | −$30.2M | −$14.7M |
| Tangible asset value | $75.4M | $129.9M | $84.0M | $125.2M | $234.6M | $307.3M | $354.4M | $449.0M | $284.5M | $272.7M |
| Net current asset value | −$12.6M | $34.6M | −$16.6M | $8.5M | $79.8M | $154.7M | $279.5M | $437.1M | $276.2M | $255.2M |
| Graham net-net per share | −$0.21 | $0.28 | −$0.50 | −$0.30 | $1.50 | $2.89 | $6.17 | $10.25 | $7.10 | $6.79 |
| Capital allocation | ||||||||||
| Dividends paid | $0 | $0 | $0 | $569,000 | $0 | $0 | — | — | — | — |
| Share buybacks (net) | — | — | $569,000 | $569,000 | — | — | $469,000 | $0 | $0 | $137,000 |
| Dividends + buybacks / free cash flow | — | 0.0% | — | — | — | — | — | — | — | — |
| Capex / revenue | 3.2% | 6.2% | 142.1% | 12.7% | 25.1% | 60.1% | 85.3% | 38.4% | 10.5% | 31.3% |
| Capex / operating cash flow | — | 11.7% | — | — | — | — | — | — | — | — |
| Capex / depreciation | 0.12 | 0.13 | 0.06 | 0.13 | 1.31 | 5.67 | 1.88 | 2.06 | 0.79 | 6.03 |
| Stock-based compensation / revenue | 8.4% | 7.6% | 693.1% | 31.5% | 15.5% | 13.6% | 177.0% | 292.3% | 200.2% | 130.8% |
| R&D / revenue | 128.2% | 218.1% | 11,608.7% | 508.6% | 117.6% | 117.6% | 605.9% | 601.4% | 314.5% | 175.1% |
| SG&A / revenue | 11.8% | 20.3% | 1,075.4% | 91.3% | 51.2% | 59.8% | 283.2% | 371.1% | 177.7% | 96.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 121.0 | 203.0 | 9,839.0 | 463.1 | 124.1 | 85.1 | 448.9 | 381.8 | 122.4 | 123.7 |
| Days of inventory on hand | — | — | 535.5 | 2,241.9 | — | 22.7 | 50.8 | 35.0 | 25.6 | 31.4 |
| Days payables outstanding | 669.5 | 750.0 | 996.9 | 4,657.0 | 243.4 | 271.0 | 723.3 | 1,688.6 | 1,334.6 | 1,830.2 |
| Cash conversion cycle (days) | -548.5 | -547.0 | 9,377.7 | -1,952.0 | -111.2 | -163.3 | -223.6 | -1,271.9 | -1,186.6 | -1,675.0 |
| Receivables turnover | 3.02 | 1.80 | 0.04 | 0.79 | 2.94 | 4.29 | 0.81 | 0.96 | 2.98 | 2.95 |
| Payables turnover | 0.55 | 0.49 | 0.37 | 0.08 | 1.50 | 1.35 | 0.50 | 0.22 | 0.27 | 0.20 |
| Inventory turnover | — | — | 0.68 | 0.16 | — | 16.11 | 7.18 | 10.43 | 14.25 | 11.62 |
| Asset turnover | 0.21 | 0.12 | 0.00 | 0.06 | 0.17 | 0.16 | 0.03 | 0.03 | 0.08 | 0.12 |
| Average receivables | $24.2M | $23.1M | $20.4M | $24.3M | $25.1M | $17.2M | $18.7M | $13.3M | $8.4M | $14.4M |
| Average payables | $18.0M | $18.9M | $20.3M | $22.6M | $24.2M | $26.9M | $22.6M | $12.7M | $9.6M | $8.5M |
| Average inventory | — | — | $10.9M | $10.9M | $803,000 | $2.3M | $1.6M | $262,500 | $183,895 | $145,266 |
| Intangibles / total assets | 0.2% | 0.3% | 0.2% | 0.3% | 0.5% | 0.3% | 0.2% | 0.3% | 0.4% | 0.4% |
Computed from CLLS's annual financial statements (latest annual report filed March 20, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CLLS valuation and financial ratios
Cellectis earned a return on equity of −65.3% in fiscal 2025. It ended the year with $119.9 million of debt and $208.7 million in cash and short-term investments, a net cash position of $88.8 million. The share count rose 180.0% from 35.8M to 100.3M over 9 years.
See the CLLS income statement, the CLLS chart for price history, or the CLLS stock overview for the latest quote and news.
CLLS key metrics FAQ
What is Cellectis's return on equity?
Cellectis's return on equity (ROE) was −65.3% in fiscal 2025: net income of -$67.6 million on average shareholders' equity of $103.5 million.
How much debt does Cellectis have?
Cellectis had total debt of $119.9 million at the end of fiscal 2025, a debt-to-equity ratio of 1.58 and more cash than debt.
Does Cellectis pay a dividend?
Cellectis did not pay a dividend in fiscal 2025.
What is Cellectis's free cash flow yield?
Cellectis generated -$42.5 million of free cash flow in fiscal 2025, a free cash flow yield of −8.8% on its market value at year-end ($485.4 million).
What is Cellectis's current ratio?
Cellectis's current ratio was 1.62 at the end of fiscal 2025: current assets were 1.62 times current liabilities.